Evidence map›Paper›PMID 37292835›Full record

ArticlebioRxiv : the preprint server for biology2023

Multiomic Single Cell Sequencing Identifies Stemlike Nature of Mixed Phenotype Acute Leukemia and Provides Novel Risk Stratification.

Cheryl A C Peretz, Vanessa E Kennedy, Anushka Walia, Cyrille L Delley, Andrew Koh, Elaine Tran, Iain C Clark, Corey E Hayford, Chris D'Amato, Yi Xue and 7 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Cheryl A C PeretzDivison of Hematology and Oncology, Department of Pediatrics, USA.
Vanessa E KennedyDivision of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA, USA.
Anushka WaliaDivision of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA, USA.
Cyrille L DelleyBioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA.
Andrew KohDivision of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA, USA.
Elaine TranDivision of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA, USA.
Iain C ClarkBioengineering, University of California Berkeley, Berkeley, CA, USA.
Corey E HayfordFluent Biosciences Inc., Watertown, MA.
Chris D'AmatoFluent Biosciences Inc., Watertown, MA.
Yi XueFluent Biosciences Inc., Watertown, MA.
Kristina M FontanezFluent Biosciences Inc., Watertown, MA.
Ritu RoyHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA.
Aaron C LoganDivision of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA, USA.
Alexander E PerlDepartment of Medicine, Division of Hematology-Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Adam AbateBioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA.
Adam OlshenHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA.
Catherine C SmithHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA.

Funding

UCSF Paul Calabresi K12 Career Development Program in Clinical OncologyK12CA260225 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BERGSLAND, EMILY K, BIVONA, TREVER G · 2021 to 2025
$2.6M
New tools for highly accessible single cell RNA sequencingR44GM145185 · NIGMS · FLUENT BIOSCIENCES INC. · PI FONTANEZ, KRISTINA · 2022 to 2023
$1.7M
Commercialization of methods and reagents for high-throughput single cell analysisR44GM137648 · NIGMS · FLUENT BIOSCIENCES INC. · PI FONTANEZ, KRISTINA · 2023 to 2023
$1.1M
Illumina NovaSeq 6000 Sequencing SystemS10OD028511 · OD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHOW, ERIC D · 2020 to 2020
$583k
NCI NIH HHS K12 CA260225NIGMS NIH HHS R44 GM137648NIGMS NIH HHS R44 GM145185NIH HHS S10 OD028511
6 · The paper itself

Abstract

Mixed phenotype acute leukemia (MPAL) is a leukemia whose biologic drivers are poorly understood, therapeutic strategy remains unclear, and prognosis is poor. We performed multiomic single cell (SC) profiling of 14 newly diagnosed adult MPAL patients to characterize the immunophenotypic, genetic, and transcriptional landscapes of MPAL. We show that neither genetic profile nor transcriptome reliably correlate with specific MPAL immunophenotypes. However, progressive acquisition of mutations is associated with increased expression of immunophenotypic markers of immaturity. Using SC transcriptional profiling, we find that MPAL blasts express a stem cell-like transcriptional profile distinct from other acute leukemias and indicative of high differentiation potential. Further, patients with the highest differentiation potential demonstrated inferior survival in our dataset. A gene set score, MPAL95, derived from genes highly enriched in this cohort, is applicable to bulk RNA sequencing data and was predictive of survival in an independent patient cohort, suggesting utility for clinical risk stratification.

Identifiers

PMID37292835
PMCPMC10245585

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.